###### Strengths and limitations of this study

-   This study addresses the lack of evidence-based treatments for child mental disorders in low-resource settings through a systematic review of existing literature.

-   The study uses a broad search strategy and includes databases (ie, regional databases from WHO) that are most likely to include studies from relevant geographic areas.

-   The anticipated high degree of clinical and methodological heterogeneity among included studies may preclude a meta-analysis.

Introduction {#s1}
============

Significance {#s1a}
------------

Disruptive behaviour disorders (DBDs) are among the most common forms of child psychopathology, and have serious long-term consequences, including academic failure, development of depression, criminal conviction as adults and suicide.[@R1] [@R2] For example, oppositional defiant disorder (ODD) and conduct disorder (CD) have an estimated worldwide prevalence of 3.3% and 3.2%, respectively.[@R3] The sizeable burden of behavioural problems over the lifespan is suggested by their early age of onset,[@R4] stability over time[@R5] [@R6] and increased risk of onset of other psychiatric disorders throughout childhood, adolescence and adulthood, including conduct disorder (for ODD),[@R7] depression[@R8] and substance abuse.[@R9] Disruptive behavioural problems are associated with low school achievement,[@R10] school dropout[@R11] and suicide.[@R12] Long-term follow-up studies have demonstrated that childhood behavioural problems are associated with later lower educational achievement,[@R13] increased delinquency[@R14] and increased risk of later serious, violent and chronic criminal offending.[@R15]

The Global Burden of Disease Study 2010 estimated that mental and substance use disorders comprise the leading causes of years lived with disability, worldwide.[@R16] Epidemiological studies have demonstrated that the majority of mental disorders have their onset in childhood or adolescence,[@R4] drawing attention to the importance of preventive and early intervention efforts in childhood. In response, the development of locally appropriate early interventions and improvement of children\'s access to care in low- and middle-income countries (LMIC) have been identified as top research priorities to advancing global mental health over the upcoming decade.[@R17]

Definitions {#s1b}
-----------

For the purposes of this study, we refer to child behavioural problems (or 'disruptive behavioural problems') as including the diagnostic categories of "Oppositional Defiant Disorder" (ODD) and "Conduct Disorder" (CD) as specified in the Diagnostic and Statistical Manual of Mental Disorders,[@R18] as well as symptoms of ODD and/or CD, such as non-compliance, aggression, disruptive classroom behaviours, destroying or stealing property, and violating rules and/or laws more broadly. These problems are also commonly referred to as 'externalising' disorders. This broad scope is chosen given ongoing debates about the construct validity of current psychiatric nosology,[@R19] the relationship between ODD and CD disorder constructs (ie, separate, overlapping or differing in degree),[@R2] and the relative dearth of studies establishing the validity of child behaviour disorder constructs outside of North America and Western Europe.[@R3] There is also significant overlap between the disorder constructs and aggressive and delinquent behaviours more generally,[@R18] and studies tend to focus on disorders versus behavioural patterns depending on academic discipline (eg, psychiatry, psychology, education, sociology, criminology).

Description of the intervention {#s1c}
-------------------------------

Interventions for disruptive behavioural problems have focused mostly on parent--child interactions, and are among the most well-researched treatments in child mental health in industrialised (high-income) countries. Currently available efficacy studies of treatments for disruptive behavioural problems support psychosocial treatments, such as behavioural parent training (BPTs), as the 'first-line' treatments.[@R22] [@R23] BPTs are based on social learning techniques and rely heavily on operant-conditioning principles carried out through differential reinforcement of desired behaviours and consistent limit setting.[@R24] The efficacy of BPTs for behavioural problems has been demonstrated across development, from early childhood[@R23] through adolescence.[@R25]

However, interventions addressing additional risk processes in the development or maintenance of disruptive behavioural problems[@R26] have also been proposed.[@R27] There is some suggestion that interventions that target risk processes at various levels of social ecological causation may be more effective than interventions targeting a single risk factor.[@R28] With regard to approaches in LMIC, a widely used strategy for addressing mental health problems is WHO\'s mental health Gap Action Programme (mhGAP).[@R31] The mhGAP Intervention Guide[@R31] supports the use of a variety of psychosocial interventions for child behavioural problems, including: family psychoeducation, parent skills training, coordination of academic supports, specific psychological therapies, family-based problem-solving techniques, and caregiver support. However, the current mhGAP recommendations for treatment of child behavioural problems are based on limited data from LMIC patient populations.

Why it is important to do this review {#s1d}
-------------------------------------

The generalisability of the available evidence for efficacy of BPTs to LMIC settings may be limited by the narrow representativeness of the study populations in the most rigorous efficacy trials, most of which were drawn from high-income (mostly English speaking) countries. For example, the 13 studies included in a Cochrane Review of behavioural treatments for early conduct disorder[@R23] were conducted in the USA (4 in Seattle, Washington, alone), Europe or Australia with patient samples ranging from 80% to 100% Caucasian. The studies in another related Cochrane Review (for conduct disorder in ages 10--17[@R25]) were all conducted either in the USA (n=7) or Australia (n=1). The generalisability of current findings is called into question by differences between sociocultural settings in parenting practices (including disciplining styles), socioeconomic and health system characteristics, patterns of risk and protective factors, the expression of distress, and help-seeking behaviour.[@R22] [@R32] For example, two meta-analyses evaluating moderators of effectiveness in parent training programmes found that low family income was the strongest moderator of treatment effect size.[@R33] [@R38]

Despite evidence of efficacy in treatment trials, response rates to psychosocial interventions for child behavioural problems remain poor for families at highest risk of long-term consequences, including those of low SES and members of marginalised cultural minority groups.[@R32] In the setting of increasing recognition of the burden of mental disorders around the world,[@R16] consensus is building around the priorities to: understand the role of social factors in the early development of mental disorders; develop locally appropriate early interventions; improve children\'s access to care in LMIC; and develop valid definitions to assess the global burden of mental disorders.[@R17] However, many questions remain about how existing evidence-based treatments can be effectively utilised, and how existing local resources can be leveraged to achieve treatment success. These challenges are especially acute for child behavioural problems, where few treatments have been tested in LMIC, and where social validity concerns are magnified given the wide cultural variety of expectations related to symptoms and proposed treatments.

Objectives {#s1e}
----------

The primary objective of this systematic review is to assess the effects of psychosocial treatments for DBDs in children (under age 18) diagnosed with ODD, CD or other disruptive behavioural problems living in LMIC. The secondary objectives of this study are to describe the range and types of psychosocial treatments used to address DBDs in LMIC and key issues related to implementation and dissemination. Specific secondary objectives related to implementation and dissemination include: to identify gaps in representativeness of study samples, threats of bias and generalisability of study findings; to describe currently utilised adaptation processes and training/supervision processes; and to estimate financial costs and human resource requirements of interventions.

Methods and analysis {#s2}
====================

Types of studies {#s2a}
----------------

All controlled comparison designs will be initially included except cross-over trial designs, given concerns about carry-over effects in behavioural interventions. If a sufficient number of randomised trials are identified, non-randomised studies may be dropped from further analysis.

Types of participants and settings {#s2b}
----------------------------------

Children and adolescents (under age 18 years) of both sexes who have been diagnosed or screened positive, as having a disruptive behaviour disorder or moderately severe behavioural problem, will be included. We will include studies primarily addressing diagnoses of disruptive behaviour-related disorders as outlined in the *Diagnostic and Statistical Manual* (editions III through 5),[@R18] [@R40] [@R41] including: Oppositional Defiant Disorder (or Oppositional Disorder in DSM-III), CD, and Disruptive Behavior Disorder Not Otherwise Specified. We will also include diagnoses of CD (F91) and its subcategories from the *International Classification of Disease* (all editions).[@R42] We will also include other related disruptive behavioural problems diagnosed by the use of a previously validated diagnostic or screening instrument primarily addressing problems related to behaviours considered disruptive, oppositional, defiant, or otherwise rule-breaking. We will exclude studies primarily addressing Attention Deficit/Hyperactivity Disorder or other mental disorders. We will include studies conducted among persons living in LMIC, as defined by the World Bank.[@R43] We will include studies conducted in any practice setting, including, but not limited to: clinics, schools, community, hospitals and juvenile justice systems. We will exclude studies conducted in high-income countries.

Types of interventions {#s2c}
----------------------

Interventions will include any 'active' psychosocial treatment, including, but not limited to: individual, family, or group therapies; education; training; or guidance that primarily targets: children, parents, families, or teachers. We will also include system-wide interventions targeting ecological risk factors, including, but not limited to: school policies, neighbourhood or community factors, and family economic interventions, providing that they meet the other inclusion criteria. Comparison groups may include: no treatment, wait list controls, 'treatment as usual' groups, or 'inactive controls'.

Types of outcome measures {#s2d}
-------------------------

### Primary outcomes {#s2d1}

Disruptive behavioural problems/symptoms (measured with the Child Behavior Checklist,[@R44] Strengths and Difficulties Questionnaire,[@R45] or other validated scales).

### Secondary outcomes {#s2d2}

-   Positive mental health outcomes (eg, prosocial behaviours).

-   Functioning (measured with Child Function Impairment Measure[@R46] or with any other commonly used measure).

-   (Juvenile) justice contact (number of arrests, incarcerations, or other contacts with juvenile justice authorities).

-   Institutionalisation (number of days in an institutional setting).

-   Hospitalisation (number of hospitalisations or number of days in hospital).

-   Academic outcomes (number of school absences, suspensions or expulsions).

-   Parental distress or mental health (measured with the Parenting Stress Index,[@R47] General Health Questionnaire[@R48] or other commonly used measures).

-   Parenting skills, attitudes or behaviours (including discipline patterns and abuse towards child; measured with the Home Observation for Measurement of the Environment,[@R49] or other commonly used measures).

-   Loss to follow-up.

Timing of outcome assessment {#s2e}
----------------------------

Measurements at any time point will be eligible for inclusion. In the case of assessment at multiple time points, the last assessment for which comparative data is available will be used.

Search methods for identification of studies {#s2f}
--------------------------------------------

The search strategy will be developed in consultation with information specialists at the Johns Hopkins Medical Institutions Welch Library (see online supplementary appendix S1 for a preliminary search strategy for MEDLINE). We will search the following electronic databases for primary studies: MEDLINE, PsycINFO, CENTRAL and the World Health Organization Global Health Library regional indexes (AIM (AFRRO), IMEMR (EMRO), IMSEAR (SEARO, WPRIM, WPRO)). We will also search the reference lists from articles of interest, including previous systematic reviews on related topics. We will also identify ongoing or incomplete studies by searching the metaRegister of Controlled Trials. We will not exclude studies based on language of publication (translation will be sought).

Data collection and analysis {#s2g}
----------------------------

### Selection of studies {#s2g1}

Two authors will independently screen the search results (titles and abstracts) for eligibility. For studies identified as possibly eligible by either of the reviewers, we will search for the full-text article. Two authors will then review the full-text articles for final inclusion based on the study inclusion/exclusion criteria. Reasons for exclusion will be noted for each excluded study. Disagreements will be resolved through discussion with a third author.

### Data extraction and management {#s2g2}

Two study authors will independently review the full-text articles and extract relevant data fields using a structured, standardised online data collection form. Prior to data collection, we will pilot the form on at least four included studies. Disagreements will be resolved by discussion between the study authors; if the initial reviewers do not achieve consensus, a third author will resolve the disagreement. We will contact the corresponding authors of included articles to clarify questions, and request additional data not included in the original publication. We will extract the following data from each included study: Geographic setting (country(ies), rural/urban)Reported study type (eg, RCT, quasiexperimental, etc)Participant allocation processes (using the standardised tool from the Cochrane handbook, Table 13.2.a[@R50])Practice setting (eg, primary care clinic, community, school, etc)Patient inclusion/exclusion criteria (diagnosis, etc)Patient characteristics (age range, %female, socioeconomic status indicators)Intervention description (reference, content, targets, duration)Intervention adaptations (from what protocol? adaptations to content, adaptations to mode of delivery)Implementer characteristics (qualifications, training, supervision)Control arm treatment descriptionPrimary outcome measure (scale, subscale, etc)Secondary outcome measuresNumber randomised (by arm)Follow-up rate and handling of dropoutsEstimate of effect size and precision (eg, OR, RR and CI, p value; univariate and multivariate)Adverse effects reported (by arm)Follow-up periodFunding source

### Assessment of risk of bias in included studies {#s2g3}

Two study authors will independently assess the risk of bias in each of the included studies using the Cochrane Collaboration\'s tool for assessing risk of bias.[@R51] Disagreements will be resolved by discussion between the study authors, or arbitration by a third author, if necessary. This tool identifies key domains through which bias is likely to be introduced into trial design, conduct or analysis: selection bias, performance bias, detection bias, attrition bias, reporting bias and other biases. For each domain, the tool identifies potential sources of bias, prompts the reviewer to provide support for a judgement, and requests the review author\'s judgement concerning the level of bias (low, unclear or high risk of bias).

Data analysis {#s2h}
-------------

### Measures of treatment effect {#s2h1}

We will first calculate the estimated treatment effect in each study using a standardised mean difference and its SD for continuous data, and OR with its 95% CI for dichotomous data. For statistically significant results, we will calculate the number needed to treat to provide benefit, and the number needed to treat to induce harm. If possible, we will perform a meta-analysis including similar studies based on target population, intervention design and outcome assessment. Meta-analysis is planned for the primary and secondary outcomes, according to their availability. All statistical tests will be performed using Stata.[@R52]

### Unit of analysis issues {#s2h2}

Given the relevance of cluster randomisation designs to the topic of interest (eg, interventions at the school or community level), cluster-randomised trials will be eligible for inclusion if they meet other inclusion criteria. Preference will be given to analyses conducted with the cluster as the unit of analysis. Sensitivity analyses will be conducted to assess the influence of including cluster-randomised trials in the overall effect estimate. Cross-over trials will not be included in this study given the high likelihood of carry-over effects of behavioural interventions. For multiarm treatment studies, all treatment arms that individually meet criteria for inclusion will be included if they are eligible for pair-wise comparison criteria.

### Dealing with missing data {#s2h3}

Dropouts will be dealt with on an intention-to-treat (ITT) basis if data is available. If ITT analysis is not available, as-treated analysis will be included. Missing precision estimates (CIs or SDs) that we are not able to obtain from the authors will be dealt with by assuming the highest SD from within the group of studies under analysis.

### Assessment of reporting biases {#s2h4}

We will assess the possibility of publication bias using funnel plots.

### Data synthesis {#s2h5}

We will present both narrative and quantitative (ie, tabular and meta-analysis, if possible) syntheses of the data, focusing on questions related to the primary and secondary objectives. For all analyses, randomised and non-randomised trials will be presented separately. Non-randomised trials will not be included in the meta-analyses. The narrative synthesis will describe the design, adaptation and implementation aspects of the studies, whereas, quantitative syntheses will elucidate the patient and provider characteristics, and primary and secondary outcomes. We will provide summary statistics describing patient and provider (sociodemographic) characteristics for each study and for all studies pooled together. We will include forest plots summarising the results of individual studies and the meta-analyses.

### Subgroup analysis and assessment of heterogeneity {#s2h6}

Heterogeneity will be assessed using χ^2^ tests for homogeneity (using p\<0.10 as a cut-off) and the I^2^ statistic. We will explore potential sources of heterogeneity by considering clinical and methodological aspects of diversity. We will address the anticipated heterogeneity by using random effects meta-analysis models. In addition, if there are a sufficient number of included studies, we will conduct subgroup analyses based on the following characteristics: primary diagnosis (ie, ODD vs CD); individual or family versus school or community interventions; specialist versus non-specialist implementers.

### Sensitivity analysis {#s2h7}

We will conduct sensitivity analyses to assess the influence of design decisions in the systematic review (eg, eligibility criteria, which data to include, and analysis methods, as identified throughout the implementation of the review, as recommended by the Cochrane Handbook (Section 9.7)[@R50] on the results of the meta-analysis. We plan to conduct a sensitivity analysis including and excluding cluster-randomised trials. We also plan to assess the influence of individual studies by using the 'leave-one-out' sensitivity method using the *metainf* command in Stata.

### Presentation of results and summary of findings table {#s2h8}

We will tabulate the sources and flow of studies throughout the review process, including reasons for exclusion, as outlined in the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement.[@R53] We will present our key findings in a 'summary of findings' table using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach,[@R54] addressing the quality of evidence, estimated effect sizes, and the secondary objectives outlined above.[@R55] [@R56] We will also record any departures from the standard methods described in Chapter 11 and Chapter 12 of the Cochrane Handbook,[@R50] along with a justification for such departures.

Ethics and dissemination {#s2i}
------------------------

### Ethical issues {#s2i1}

The planned study relies on previously conducted studies and does not involve collection of new or identifiable data. Accordingly, no ethical review or informed consent is required.

### Publication plan {#s2i2}

This study has been registered in the International Prospective Register of Systematic Reviews (<http://www.crd.york.ac.uk/prospero>) (registration number: CRD420 14015334). The authors plan to present the findings of this review in a single published manuscript.
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